Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that oral minoxidil is associated with a higher proportional reporting of several cardiovascular adverse events compared to topical minoxidil in spontaneous FDA reports, but these signals should be interpreted as hypothesis-generating rather than evidence of clinical safety.

This Cochrane Review protocol aims to evaluate the effectiveness and safety of various treatments for alopecia areata through a network meta-analysis, but no specific study findings are reported yet.

This study found that higher cumulative doses of topical minoxidil solution were strongly associated with improved hair density and thickness in male patients with androgenic alopecia over a 24-week period.

This case report describes a 20-year-old female who ingested an unknown quantity of minoxidil tablets in an overdose, presenting with cardiovascular symptoms, but her condition stabilized after supportive care.

Using 5% minoxidil foam twice daily can help regrow hair, especially in younger men aged 20-30.

This study found that liposomal formulations improved minoxidil delivery to skin layers compared to niosomes and a control solution, suggesting enhanced potential for topical hair loss treatment.

Minoxidil can help grow hair and make hair follicles bigger, but it can also cause side effects.

Minoxidil can cause dangerous fluid buildup around the heart.

This study found that neutral liposomes were most effective at delivering minoxidil into pilosebaceous units compared to other tested formulations.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

In this study, a nanoemulsion containing lavender, peppermint, and rosemary essential oils was developed and shown to promote hair growth in mice at a rate comparable to 2% topical minoxidil, suggesting a promising natural alternative due to its antioxidant and anti-inflammatory effects.

Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.

This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.

In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.

In this study, tapering prednisone followed by 2% topical minoxidil helped limit hair loss in some patients with alopecia areata, with 30% to 47% showing over 25% hair regrowth initially.

This study found that a once-daily 5% minoxidil topical foam is as effective as a twice-daily 2% minoxidil topical solution for hair growth in women with androgenetic alopecia, with fewer side effects and greater styling convenience.

This review indicates that most studies reported positive effects of platelet-rich plasma injections for treating androgenic alopecia, with no major side effects, suggesting it may be a safe alternative to Minoxidil and Finasteride.

This study found that minoxidil topical solution was associated with a dose-related occurrence of hypertrichosis, especially facial hair, in women treated for androgenetic alopecia.

This study found that 2% topical minoxidil solution was significantly more effective than placebo in promoting new hair growth in women with androgenetic alopecia.

This study found that daily use of 1% pyrithione zinc shampoo modestly improved hair growth over 26 weeks, although these effects were less than those of 5% minoxidil.

Minoxidil absorbs poorly through skin, with low risk of side effects at 1-2% concentration.

This study concluded that a combined once-daily solution of 5% minoxidil and 0.01% tretinoin is as effective and safe as the conventional twice-daily 5% minoxidil application for treating androgenetic alopecia in men.

This study found that topical minoxidil solution is a safe treatment for androgenetic alopecia, with no increase in cardiovascular events or adverse pregnancy outcomes observed.

This pilot study found that a multimodal minoxidil microemulsion with diclofenac and tea tree oil was more effective and safer than minoxidil alone for treating androgenic alopecia over 32 weeks.

In this noninferiority study, researchers found that a 0.2% caffeine-based topical liquid was not less effective than 5% minoxidil solution in improving hair growth in men with androgenetic alopecia over six months.

In this study, 5% minoxidil significantly improved outcomes for children and adults with patchy alopecia areata compared to placebo, with moderate quality evidence and no severe adverse events reported, though more research is needed to address remaining uncertainties.

This study reported that using 5% minoxidil topical foam twice daily improved hair density and width in both the frontotemporal and vertex regions of men with moderate androgenetic alopecia.

This study reported that low-dose oral minoxidil is generally safe for treating various types of hair loss, though it may cause hypertrichosis and pedal edema, especially at higher doses.

This study reported that combined oral finasteride and topical 5% minoxidil treatment in men with male-pattern hair loss improved hair growth by initiating anagen in pre-existing but deficient follicles, yet the growth rates remained unchanged and did not normalize hair productivity.